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Abstract
Intravenous drug use is associated with infective endocarditis. Besides, it does 
appear that left-sided infective endocarditis is a feature of general population, 
whereas right-sided infective endocarditis is common in intravenous drug users. 
The most common etiology of right-sided infective endocarditis in intravenous 
drug users is Staphylococcus aureus in about 75% followed by streptococci, Gram-
negative bacilli and fungi. In case of intravenous drug users with infective endocar-
ditis, optimal treatment strategies lack a general consensus. Additionally, the best 
indication and timing of surgery are debatable. To overcome these problems, the 
early and complete surgical debridement of infected tissue together with microbial 
therapy assures a good prognosis in the long term.
Keywords: endocarditis, drug-associated endocarditis, intravenous drug abuser 
endocarditis, intravenous drug users, right heart endocarditis
1. Introduction
Infective endocarditis (IE) is a rare infectious disease with elevated morbidity 
and mortality [1]. Intravenous drug use is associated with infective endocarditis 
(IE) [2]. To the best of our knowledge, IE accounts for 2–5% per year among the 
intravenous drug users (IDUs) [3–6]. Approximately 41% of IDUs with bacteremia 
will develop IE [7]. Conversely, it is widely agreed that intravenous drug users 
(IDUs) diagnosed with IE are mainly white young males [8–12].
Right-sided infective endocarditis has been mainly defined among IDUs [13–15]. 
Generally, right-sided IE comprises 5–10% of cases with IE [16–18]. It does appear 
that left-sided IE is a feature of general population, whereas right-sided IE is 
common in IDUs [19–21]. To further characterize, IDUs may present in 86% cases 
right-sided IE, whereas 14% have left-sided IE with or without right-sided IE [21]. 
However, some older data outlines that the IDUs group may present equal incidence 
of left-sided and right-sided IE [22].
Common predisposing factors for right-sided IE are the intravenous drug users 
(IDUs), catheter-related infections, pacemaker or defibrillators wires, intracardiac 
devices (catheters for hemodialysis; tricuspid prosthetic valve), right heart cath-
eterization, congenital heart defects, sepsis, and alcoholism [13–15, 23]. In case of 
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the right-sided IE, tricuspid valve is affected in 90% cases [21], whereas pulmonic 
valve represents about 10% from right-sided IE cases [3, 18, 24]. Up to now, isolated 
right-sided IE involving the pulmonary valve, the eustachian valve, interventricular 
septum, or right ventricular free wall have been described [17, 21, 25].
2. Microbiology
According to current evidence, IE among IDUs presents a large spectrum of 
microbial pathogens (Table 1) [26–31].
Pathogens as Pseudomonas aeruginosa, other gram-negative microorganisms, 
fungi, enterococci, streptococci, and polymicrobial infections occur less fre-
quently [16]. Importantly, other pathogens noted in IDUs are oral bacteria such as 
Prevotella intermedia, Haemophilus parainfluenzae, S. constellatus, and E. corrodens 
[32–36].
The most common etiology of right-sided IE in IDUs is Staphylococcus aureus 
(S. aureus) in about 75% [1, 4, 6, 37–39] followed by streptococci, Gram-negative 
bacilli, and fungi [40]. In fact, published data supports the involvement of S. 
aureus among IDUs in 40–74% cases of IE [38, 41, 42]. S. aureus is the most com-
mon cause of tricuspid valve endocarditis regardless of associated risk factors in 
IDUs [1, 4, 16, 18, 43].
The incidence of negative blood cultures is reported as 2.5–31% and is associated 
with delayed diagnosis and treatment [44], with large vegetations [45], and with 
highest morbidity and mortality [16, 45, 46].
Regarding HIV, a prevalence of HIV as high as 60% among IDUs has been 
reported by centers from Europe and the USA [11, 40]. HIV is more common 
among IDUs with right-sided IE than left-sided IE [47].
Polymicrobial endocarditis is characteristically for IDUs [48] and may involve 
microorganisms such as Bartonella spp., Candida spp., or Tropheryma whipplei [49]. 
The presence of E. corrodens should aware the likelihood of polymicrobial IE with 
embolic complications and relapses. In fact, there is a synergism between strepto-
cocci and E. corrodens [50–52].
• Staphylococcus aureus and coagulase-negative staphylococci,
• group A streptococci,
• P. aeruginosa,
• HACEK organisms (Haemophilus aphrophilus, Actinobacillus actinomycetemcomitans, Cardiobacterium 
hominis, Eikenella corrodens, and Kingella kingae),
• Tetanus (Clostridium tetani),
• Anthrax (Bacillus anthracis),
• wound botulism (Clostridium botulinum),
• tuberculosis,
• diphtheria (Corynebacterium diphtheriae),
• viruses (HIV, HBV with HDV, HCV, and HTLV),
• fungal infections (Candida spp. and Aspergillus spp.),
• parasitic infections (malaria and leishmaniasis)
Table 1. 
Spectrum of microbial pathogens may constitute comorbidity in IDUs [26–31].
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3. Diagnosis
History and classic Oslerian manifestations (persistent bacteremia or funge-
mia, active valvulitis, immunological vascular phenomena, and peripheral 
emboli) help with a straightforward diagnosis in IE [1]. Typical clinical mani-
festations of IE comprise fever, positive blood cultures, and valvular vegetations 
on echocardiography [53]. IE should be suspected in the presence of fever and 
embolic phenomena [16]. Persistent fever and bacteremia are common manifesta-
tions of tricuspid valve IE [16].
Clinical manifestations are usually limited in the early IE of IDUs, right-sided 
endocarditis and S. aureus [1]. Right-sided IE mainly present fever, cough, hemop-
tysis, dyspnea caused by pulmonary emboli, anemia, and no systemic emboli 
[23]. Characteristically, right-sided IE does not develop immunological vascular 
phenomena (splinter hemorrhages, Roth spots, and glomerulonephritis) and the 
peripheral emboli [1]. Right-sided IE can be associated with septic pulmonary 
emboli [1]. In fact, pulmonary embolism is often present in right-sided IE and 
pacemaker wires IE [16].
Usually, the association of clinical findings, positive blood cultures, and posi-
tive echocardiography set up the diagnosis [23]. However, these typical clinical 
manifestations of IE are often absent among IDUs, especially in those infected with 
S. aureus and HACEK (Haemophilus species, Actinobacillus actinomycetemcomitans, 
Cardiobacterium hominis, Eikenella corrodens, Kingella kingae) [54]. Common com-
plications of right-sided IE are valvular regurgitations, cardiac abscess, and septic 
pulmonary emboli [55].
Relapse and reinfection are two types of recurrence [16]. Basically, recurrence 
within 6 months of same IE produced by same microorganisms is termed relapse 
[55]. Reinfection or recurrent IE refers to the recurrence of same IE with same 
microorganisms after 6 months from initial episode [53]. Recurrent IE has higher 
frequency in IDUs with increased valve replacement [16] with a reported inci-
dence as 41% [56].
The landmark lesion of IE is the vegetation (Figure 1) [57]. In this context, IDUs 
population with vegetations >20 mm may present higher embolic risk [58] and 
higher mortality as well [25, 58, 59].
The cornerstone of imaging diagnosing for infective endocarditis is echocar-
diography [16]. Transthoracic echocardiography (TTE) and/or transesophageal 
echocardiography (TOE) are vital in the diagnosis of any IE [16]. TTE is the first 
line recommendation either for native valve endocarditis or for prosthetic valve 
endocarditis. In case of suspected native valve endocarditis, TTE has a sensitivity of 
50–90% and a specificity of 90% [60]. For IE with vegetation, TTE has a moderate 
sensitivity (75%) and high specificity (>90%) [61]. For suspected prosthetic valve 
endocarditis, TTE has a reduced sensitivity of 40–70%. However, TTE comes up 
with significant information regarding ventricular size and function, and “hemo-
dynamic severity of valve lesions” [60]. Major criteria in the diagnosis of IE are 
represented by three echocardiographic features: vegetation, abscess or pseudoa-
neurysm, and prosthetic valve with new dehiscence [16]. Moreover, TTE provides 
useful information in the diagnosis of anterior prosthetic aortic valve abscesses, 
which are difficult to be seen on TEE [60].
TOE is recommended when TTE is nondiagnostic or positive, suspected com-
plications, or in presence of intracardiac device leads [60]. In case of native valve 
endocarditis, TOE has a sensitivity of 90–100% and a specificity of 90% for reveal-
ing vegetations. As such, TOE is highly superior to TOE regarding the detection 
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of abscesses, perforations, and fistulae [60]. TOE has higher sensibility in the 
detection of pulmonary vegetations [62]. When clinical manifestations sustain IE 
with negative or unclear TTE, TOE has high sensitivity (>90%) and may reveal: (1) 
vegetations; (2) paravalvular or intracardiac abscess, (3) new valvular regurgita-
tions, and (4) prosthetic valve dehiscence (Figure 2) [57, 63, 64].
Currently, 3D TOE provides useful information about the morphology and size 
of vegetation, evaluation of perivalvular extension, dehiscence of prosthetic valve, 
and valve perforation [65].
Figure 1. 
Macroscopy and microscopy of the involved tricuspid valve and vegetation. (a) Yellow arrowhead: the 
large vegetation, blue arrowhead: rupture main chordae tendineae. (b) Blue arrowheads: multiple 
verrucous nodular vegetation on the atrial surface of leaflet. (c) Resected tricuspid valve. Blue 
arrowheads: multiple small vegetations, yellow arrowhead: rupture main chordae tendineae. (d) 
Microscopy of the vegetation adhered to the leaflet, magnification 4×, hematoxylin and Eosin stain. 
(e) Enlarged square area in (e) showing inflammatory cell infiltration and fibrin-platelet thrombi, 
magnification 20×, hematoxylin and Eosin stain. NOTE: every figure specifies this sentence beginning: 
From Bai et al. [57]. It is an open access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly credited.
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Other imaging techniques such as magnetic resonance imaging (MRI), mul-
tislice computed tomography (MSCT), and 18F-fluorodeoxyglucose (FDG) posi-
tron emission tomography (PET)/computed tomography (CT) are also valuable for 
the diagnosis of IE [16]. MSCT, MRI, and cardiac CT can provide greater informa-
tion when compared with TEE regarding either paravalvular anatomy or complica-
tions (e.g. mycotic aneurysms, paravalvular abscesses) with lesser prosthetic valve 
artifacts [60]. Currently, using CT imaging in the diagnosis of paravalvular lesions 
is a major criterion in the 2015 ESC guidelines on IE [16].
Figure 2. 
Transesophageal echocardiography images of the patient before surgery. (a) Tricuspid regurgitation, Yellow 
arrowhead: wide and reversed blood flow signals at TV site. (b) A large vegetation formation. Yellow 
arrowhead: a large vegetation adheres to anterior leaflet of TV. (c) Suspicious multiple vegetations on 3D 
echo image. Yellow arrowheads: multiple verrucous abnormal nodular projections on the leaflet surface. RA 
right atrium, RV right ventricle, LA left atrium, LV left ventricle, TV tricuspid valve. NOTE: every figure 
specifies this sentence beginning: From Bai et al. [57]. It is an open access article distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits 




Modified Duke criteria (2000) for diagnostic classification are well-known [64] 
and reviewed by 2015 ESC Guidelines for the management of infective endocarditis 
[16]. Only that, these modified Duke criteria have poorer diagnostic precision in the 
early diagnosis of IE from IDUs, which present fewer typical clinical manifestations 
[16]. The addition of imagistic techniques cardiac/whole-body CT scan, cerebral 
MRI, 18F-FDG PET/CT, and radiolabelled leucocyte SPECT/CT may increase accu-
racy of the modified Duke criteria in IDUs. To sum up, these modified Duke criteria 
are useful, but they do not substitute the decision of a multidisciplinary team or of 
the “Endocarditis Team” that is defined later [16].
4. Treatment
The initial treatment of IE is empirical in majority of cases [1]. Consistent with pub-
lished data, the main effective treatment is medical therapy, whilst surgery is a choice 
in smaller cases [16]. So that, medical treatment in right-sided IE of IDUs is usually 
effective with good prognosis up to 80% cases [16, 23, 66].
S. aureus is the most frequent cause of IE in IDUs; as a result, medical treatment 
should cover this pathogen [16]. Short courses of antimicrobial therapy in right-
sided IE with S. aureus in IDUs assure high cure rates (>85%) [1].
A short course (2 weeks) with oxacillin or cloxacillin is mainly sufficient [16]. 
Initial therapy comprises penicillinase-resistant penicillins, vancomycin, or dapto-
mycin in combination with gentamicin [16]. Short course (2 weeks) with oxacillin 
or cloxacillin is mainly efficient for isolated tricuspid IE with good compliance to 
therapy, vegetation <20 mm, MSSA, without empyema or other metastatic sites of 
infection, without prosthetic valve or left-sided IE, without cardiac/extracardiac 
complications and without severe immunosuppression (<200CD4 cells/μL) with/
without AIDS. Anti-pseudomonas agent should be added in pentazocine addict 
[59]. Antifungal therapy for Candida spp. is added when an IDU utilizes brown 
heroin combined with lemon juice [67].
A traditional approach for the treatment of right-sided IE is the regimen formed 
from gentamicin with nafcillin or oxacillin. Another approach of IDUs with right-
sided S. aureus IE and no other complications (e.g. aortic or mitral valve involve-
ment, extra pulmonary infections or meningitis, renal failure, MRSA infection) is 
the antimicrobial coverage with short-course (2 weeks) of beta-lactam plus amino-
glycoside that may be greatly successful [1]. Current guidelines still suggest the use 
of gentamicin, but some available data suggest that it might be unnecessary [68].
Moreover, daptomycin monotherapy is approved for the therapy of S. aureus 
bacteremia or right-sided S. aureus IE [69]. If laboratory evaluation shows opiate 
withdrawal, 10–20 mg of long-acting methadone can be prescribed until the regular 
doses are established [70].
To sum up, it is problematic to treat IE in IDUs because of the frequent exposures 
to virulent microorganisms; poor compliance with treatment; illegal drug use or 
withdrawal manifestations during hospitalization; opioid maintenance therapy; 
and early self-discharge or long hospitalization [70, 71]. Regardless of correct 
antimicrobial therapy, IDUs develop relapsing IE [56, 72, 73].
5. Surgery
Surgery is not a contraindication for IDUs with IE [4]. However, surgery indica-
tions are complex and are based on the clinical manifestations, associated risk fac-
tors (e.g. age, microorganisms, size of vegetation, perivalvular infection, embolism, 
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heart failure, and other associated comorbidities) and the expertise of surgery team 
[1]. A multidisciplinary team or the “Endocarditis team” with knowledge in cardiol-
ogy, infectious diseases, microbiologists, imaging, neurologists, neurosurgeons, 
and cardiothoracic surgery should provide decisions regarding the indication and 
timing of surgery [1]. Cardiac surgery in IDUs with IE aims to remove infection 
with hemodynamics stabilization hemodynamic may be suggested for IDUs [74].
In terms of surgery, right-sided IE has better outcomes than left-sided IE [1]. 
General approach of IDUs with right-sided IE is medical therapy and to delay as 
much as possible the use of valve prostheses [1].
Surgical treatment indications for right-sided IE are following [1, 16, 28, 75]:
• TV vegetations >20 mm after recurrent septic pulmonary emboli with or  
without right heart failure;
• Severe tricuspid regurgitation with right heart failure unresponsive to  
medical therapy;
• IE with fungi or persistent bacteremia with virulent microorganisms for at  
least 7 days (e.g., S. aureus, P. aeruginosa) regardless of the antimicrobial therapy.
5.1 Timing of surgery
Only 5–16% of IDUs needs surgery [76–78]. However, if left-sided IE has clear 
indications for early surgery, and the indications for early surgery in right-sided IE 
are not established presently [79].
The strategy to delay surgery until the microbial therapy is accomplished and 
may decrease morbidity and mortality rates significantly. In keeping with published 
data, early surgery is a choice in case of IE with Staphylococcus aureus or fungal infec-
tion [1, 16, 80]. Early surgery of tricuspid valve IE is considered when associates 
(1) atrial septal defect; (2) prosthetic valve endocarditis; (3) infected pacing leads; 
(4) indwelling catheters; and (5) simultaneous left-sided IE [81, 82]. Additionally, 
development of bacteremia or pulmonary septic emboli also has early surgery.
5.2 Surgical techniques
The principles of surgery for tricuspid valve IE comprise debridement of infected 
tissue; excision of vegetations with valve conservation or valve repair; and removal 
of the TV with its replacement [16, 76, 81]. In case of native pulmonary valve, its 
preservation is usually recommended. If pulmonary replacement is mandatory, the 
utilization of a homograft or xenograft is favored.
Various techniques that are used in cardiac surgery for right-sided IE [71, 81, 82]:
• vegetectomy (excision of vegetations)
• valvulectomy (total removal of valve leaflets and chordate tendineae)
• valvectomy (valve excision)
• reconstruction of the cusps (e.g. bicuspidization or conversion to a bicuspid valve)
• pericardial patch augmentation
• Kay’s or De Vega’s annuloplasty
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• annuloplasty ring implantation
• synthetic or expanded polytetrafluoroethylene (PTFE) neo-chords
• valve replacement (bioprosthetic, mechanical prostheses).
Importantly, first line of surgical techniques in IDUs is vegetectomy and valve 
repair [23].
Valve repair is mainly achieved with autologous pericardial patch, artificial 
chordae, and simple annuloplasty with sutures (Kay’s or De Vega annuloplasty) [23]. 
Ruptured chordae may be restored with polytetrafluoroethylene neo-chordae [16].
In a single perforated valve leaflet (cusp) can be used either untreated or glu-
taraldehyde-treated autologous or bovine pericardial patch [16]. Pericardial patch 
reconstruction aims to avoid the use of any prosthetic materials [23]. Autologous 
pericardial patch repairs small defects by direct closure in case of one leaflet. It is 
also used in wide excision or debridement of one leaflet or two leaflets [23].
Bicuspidalization annuloplasty is done after total excision of the posterior 
leaflet of tricuspid valve. Importantly, septal leaflet excision of TV has high risk of 
postoperative atrio-ventricular block [23]. This technique is accomplished either by 
Kay’s annuloplasty or De Vega annuloplasty. Both Kay’s annuloplasty and De Vega 
annuloplasty are the first choices indication for valve repair mainly in IDUs [23]. 
After broad resection (>75%) of the anterior leaflet of TV, it is recommended using 
of prosthetic or pericardial annular ring [23].
Kay’s annuloplasty is mainly done after the total resection of a leaflet, and it is 
accomplished by the placement of fixing sutures in the corresponding segment of 
annulus to create a bicuspid valve [23].
De Vega annuloplasty (Figures 3 and 4) is based on fixing of two semi-circular 
purse string sutures between the anteroseptal commissure to the posteroseptal 
commissure with tricuspid annular reduction [23, 83]. This leads to the coaptation 
of the residual two leaflets.
Valve replacement. Valve replacement is required in case of a large destroyed valve 
with increased pulmonary pressures and pulmonary vascular resistance [16, 76, 81].  
It also requires the absence of drug addiction during surgery and after surgery [23]. 
Presently, it is recommended tricuspid valve excision for right-sided IE in IDUs [23].  
Figure 3. 
Operative procedures. (A) After the prolapsed leaflet segments and chordae were excised, the anterior 
commissural defect was made. (B) The defect was closed with an elliptical pericardial patch of 2.0 × 1.0 cm size. 
An adjustable DeVega-type annuloplasty using two continuous 5–0 Polypropylene sutures was performed to select 
an appropriate-size ring for complete leaflet coaptation. (C) A 26-mm Edward MC3 ring was placed using two 
interrupted, pledgeted 2–0 Dacron sutures and two continuous 3–0 polypropylene sutures. The anterior horn of 
the rigid ring (black arrow) was sutured to the medial end of the patch. NOTE: every figure specifies this sentence 
beginning: From Kim et al. [83]. It is an open access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly credited.
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Valve replacement in IDUs is correlated with greater risk for recurrent infection and 
redo surgery (re-operation) [81]. It seems that mechanical prostheses and xenografts 
have similar outcomes [16]. However, recurrence of IE is mainly unchanged for 
mechanical and bioprosthetic valves [84]. Placement of a bioprosthetic valve may be 
challenging in case of IDUs with endocarditis considering the low compliance of IDUs 
for any treatment, risk of recurrent infections, risk of redo surgery, or valve genera-
tion. HIV is not a contraindication for surgery having good prognosis after it [85].
An important concern of tricuspid valve surgery is the damage of conduction 
system, which is higher in TV replacement [81, 86]. For instance, in case of 910 
surgeries for tricuspid valve IE, there was higher risk of heart block in TV replace-
ment (16%) versus TV repair (3%, p < 0.0001) [86].
Despite of published data supporting the greater risk of morbidity and mortal-
ity for multiple valve endocarditis [87], Weymann et al. outlined that single-valve 
endocarditis or multiple valve involvement have no different operative or postop-
erative risks [88]. In any type of prosthesis, survival on long-term is similar in any 
tricuspid valve replacement with prosthesis [89, 90]. Homograft tissue valve may be 
used after valvectomy mainly with cryopreserved mitral homograft [23].
IDUs have a greater mortality rate in comparison with the general population 
[91, 92]. However, right-sided IE treated surgically has good outcomes in the 
early, mid-term, and long-term [86]. Significant risk factors for poor prognosis in 
IDUs treated surgically are interrelated with the Staphylococcus aureus and fungi or 
polymicrobial IE, late presentation in critical condition, with the vegetation size, 
and with left-sided IE [93].
Taking into account the current guidelines of The Society of Thoracic Surgeons 
Workforce on Evidence Based Surgery, European Society of Cardiology, and The 
European Association for Cardio-Thoracic Surgery, the first line recommendation  
(Class Ia) in IE for IDUs is the excision of infected tissue (vegetation) with valve 
repair. Furthermore, the second line recommendation (Class IIa) is tricuspid valve 
replacement. Bioprosthesis is the principal choice in TV replacement in IDUs, 
because mechanical valve needs long life anticoagulation [16, 23, 39, 81, 94, 95].
A conservative approach is recommended by European Society of Cardiology in 
case of IDUs which present greater risk of recurrent infection. When valve replace-
ment is necessary, bioprosthesis decreases the thromboembolism risk with no 
anticoagulant therapy on long term. On the other side, younger IDUs are disposed 
Figure 4. 
Operative findings. (A) The anterior commissure defect was closed with a patch (white arrow) and a rigid ring 
was placed along the functional valve opening. (B) The valve leaflets showed complete coaptation (white arrow) 
on saline test. NOTE: every figure specifies this sentence beginning: From Kim et al. [83]. It is an open access 
article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/
licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly credited.
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to redo surgery or re-operation either because of recurrent infection or valve 
degeneration (Figure 5) [16, 96]. Moreover, valvectomy is the last choice to valve 
repair or valve replacement in IDUs with greater risk of recurrent infection. The 
valvectomy technique eludes the use of prosthetic material but is limited by residual 
severe tricuspid regurgitation with right heart failure. Published data supports this 
technique because of its long-term survival after complete valvectomy. For instance, 
one study of Gaca et al. reports tricuspid valvectomy as first choice only in 66 cases 
from 910 patients (7.3%) [86].
Recurrence of IE is characteristically for IDUs [23, 97]. However, the best indica-
tion and timing of surgery are debatable [98]. Prognosis of IE in IDUs has good 
outcomes with mortality <5% [23]. Right-sided IE has a good prognosis with lower 
in-hospital mortality. As well, right-sided IE has a lower morbidity and mortality 
with better prognosis than left-sided IE but with greater early mortality rate [11, 
21, 99]. Higher mortality in IDUs with right-sided IE is associated with vegetations 
>20 mm, fungal endocarditis, bacteremia, and older age [4, 13, 21, 59]. To sum 
up, the early and complete surgical debridement of infected tissue together with 
microbial therapy assures a good prognosis on long term [88].
6. Conclusions
Right-sided IE is the primarily disease that affects IDUs and patients with 
congenital heart diseases [16]. Diagnostic findings comprise fever and respiratory 
symptoms [16]. In the main part of cases, S. aureus is responsible pathogen [16]. For 
IDUs with IE, optimal treatment strategies lack a general consensus. Majority of 
Figure 5. 
The damaged bioprosthetic tricuspid valve with vegetations. NOTE: every figure specifies this sentence 
beginning: From Chen et al. [96]. It is an open access article distributed under the terms of the Creative 
Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) 
and the source, provide a link to the Creative Commons license, and indicate if changes were made.
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strategies are applied based on the team experience and the patient. Furthermore, 
this absence of evidence-based guidelines highlights that any IE should be managed 
by an “Endocarditis Team” [86]. Surgery is a choice only for difficult evolution, 
failure of medical therapy, or recurrent septic emboli to the lungs or paradoxical 
emboli [16].
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